Analysis of Recurrence and Disease-Free Survival Outcomes of Fertility- Preserving Surgical Interventions in Borderline Ovarian Tumours
Özet
Borderline ovarian tumours (BOTs) are a heterogeneous group of tumours that occur predominantly in women of childbearing age and generally have a good prognosis. This section comprehensively addresses the diagnostic features, epidemiological trends, clinical management, and the impact of fertility-preserving surgery on oncological outcomes of BOTs. In our study, a large cohort of patients treated over a 20-year period was retrospectively evaluated; recurrence rates were found to be significantly higher in patients who underwent fertility-preserving surgery, but the vast majority of these recurrences were non-invasive and successfully treated. The extent of the surgical approach, particularly the choice between cystectomy and unilateral salpingo-oophorectomy, plays a decisive role in the risk of recurrence. In contrast, when fertility outcomes are examined, pregnancy rates are satisfactory in patients who underwent conservative surgery. The lack of a significant effect of lymphadenectomy on recurrence highlights the need to individualise the extent of surgery in the management of BOTs. Overall, the data indicate that treatment planning in BOT patients should balance oncological safety and fertility preservation, and that long-term follow-up data are critical in determining the optimal clinical approach in this patient group.
Referanslar
Lenhard MS, Mitterer S, Kümper C, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009 Aug;145(2):189–94.
Tempfer CB, Polterauer S, Bentz EK, et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol. 2007 Nov;107(2):248–52.
Cadron I, Amant F, Van Gorp T, et al. The management of borderline tumours of the ovary. Curr Opin Oncol. 2006 Sep;18(5):488–93.
Coumbos A, Sehouli J, Chekerov R, et al. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. Br J Cancer. 2009 Jun 2;100(11):1731–8.
Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973 May;31(5):1031–45.
Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005 Feb;18 Suppl 2:S33-50.
Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998 Mar 15;82(6):1096–103.
Roth LM, Emerson RE, Ulbright TM. Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol. 2003 Sep;27(9):1253–9.
Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol. 2000 Nov;24(11):1465–79.
Cuatrecasas M, Catasus L, Palacios J, et al. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol. 2009 Apr;33(4):556–67.
Ali RH, Seidman JD, Luk M, et al. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. Int J Gynecol Pathol. 2012 Nov;31(6):499–506.
Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol. 2006 Sep;49(3):517–25.
Chen S, Leitao MM, Tornos C, et al. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol. 2005 Jul;18(7):903–11.
Skírnisdóttir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008 Oct 15;123(8):1897–901.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3–14.
Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003 Mar 20;104(2):228–32.
Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14.
Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006 Dec;103(3):1122–9.
Stratton JF, Pharoah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998 May;105(5):493–9.
Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S8-10; discussion S11-13.
Tokunaga H, Shimada M, Ishikawa M, et al. TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. Jpn J Clin Oncol. 2019 Apr 1;49(4):311–20.
Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005 Jun;29(6):707–23.
Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal ‘implants’. Am J Surg Pathol. 1992 Jun;16(6):577–83.
Rao GG, Skinner E, Gehrig PA, et al. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol. 2004 Aug;104(2):261–6.
Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic ‘stage I’ ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004 Aug;40(12):1842–9.
Boran N, Cil AP, Tulunay G, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol. 2005 Jun;97(3):845–51.
Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006 Jan;100(1):185–91.
Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003 May;79(5):1216–21.
Fan Y, Zhang YF, Wang MY, et al. Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis. Gynecol Oncol. 2021 Sep;162(3):797–803.
Maltaris T, Boehm D, Dittrich R, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 2006 Dec;103(3):1109–21.
Makar AP, Tropé C. Fertility preservation in gynecologic cancer. Acta Obstet Gynecol Scand. 2001 Sep;80(9):794–802.
Plett H, Harter P, Ataseven B, et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol. 2020 May;157(2):411–7.
Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001 May 15;19(10):2658–64.
Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer. 1993 Mar 1;71(5):1810–20.
